In vitro repositioning therapy with olaparib, temozolomide and oxaliplatin in glioblastoma cell lines: U118, U87, U251, H4 and human fibroblasts
The proposed multidrug repositioning chemotherapy produced a therapeutic effect at lower doses, suggesting that it is potentially a safer and more effective treatment option.
Authors
- Beata Biesaga (ORCID: https://orcid.org/0000-0001-9680-8140)
- Jakub Jończyk (ORCID: https://orcid.org/0000-0002-9731-908X)
- Justyna Miszczyk (ORCID: https://orcid.org/0000-0001-7226-1750)
- Tomasz Skóra (ORCID: https://orcid.org/0000-0001-6322-0615)
- Anna Czopek (ORCID: https://orcid.org/0000-0002-1448-9826)
- D Wisniewski
- Monika Krzyżowska (ORCID: https://orcid.org/0009-0001-2595-2767)
- Anna Zając (ORCID: https://orcid.org/0000-0003-1558-4777)
- Paula Ajersch
- Karolina Pazdan
- Filip Michałkiewicz
Institutions
- Wrocław University of Science and Technology (PL)
- Jagiellonian University (PL)
- Institute of Nuclear Physics, Polish Academy of Sciences (PL)
- National Institute of Oncology (HU)
- AGH University of Krakow (PL)
Publication Details
- Journal
- Pharmacological Reports
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1007/s43440-025-00783-w
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Uniwersytet Jagielloński Collegium Medicum
- Narodowym Centrum Nauki
- Ministerstwo Edukacji i Nauki